Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
AssigneeExocell, Inc.
InventorMargo P. Cohen
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin,, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.
Claims9
A compound selected from those having the following structure:
- wherein:
- R′3, R′4, R′5, R′6, R2, R3, R4, R5 and R6 are the same or different and are hydrogen, chlorine, bromine, fluorine, iodine, ethyl, ethoxy, methoxy, hydroxy, phosphate, sulfate, nitrate, amino or ethyl, and R2 and R6 are both not chlorine when R′3, R′4, R′5, R′6, R3, R4 and R5 are hydrogen;
- X is hydrogen, sodium, potassium or lithium.
A method that identifies compounds that, by binding to specific sites in albumin and thereby rendering pathophysiologically important glycatable sites inaccessible to reaction with carbohydrate, inhibits the formation of glucose adducts on albumin, wherein said albumin containing glucose adducts has pathophysiologic effects in living organisms and wherein said compounds can inhibit the formation of glucose adducts on albumin at concentrations of 300 micromolar or less.
Dependencies are inferred from the claim text.